Program
RO7568282
A development code.
Its studies are mostly in Parkinson Disease · Alzheimer Disease, led by Hoffmann-La Roche.
Furthest: phase 2, since Aug 20, 20262 company-led studies, 2 open or runningNext primary completion: Dec 15, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 22 open or running | phase 2since Aug 20, 2026 | Aug 20, 2026 | Dec 15, 2028phase 2 · NCT07781644 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2026First studies: 2 phase 2 studiesFirst studyNCT07781657, NCT07781644
Ahead
- Dec 15, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07781644
- Nov 1, 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07781657
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07781657Alzheimer Disease · United States, Australia, France and more | 2 | Recruiting | Nov 1, 2029 | 450 |
| NCT07781644Parkinson Disease · United States, China, Ireland and more | 2 | Recruiting | Dec 15, 2028 | 474 |
How it is read
Names in the registry
- “RO7568282”, 2 entries
Codes read as this program: RO7568282.
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.